LeukoStrat® FLT3 Mutation Assay 2.0 – ABI Fluorescence Detection
Acute myeloid leukemia (AML) in general has a poor prognosis. Assessment of the mutation status of the FLT3 (fms like tyrosine kinase 3) receptor gene...
LeukoStrat® CDx FLT3 Mutation Assay
Acute myelogenous leukemia (AML) in general has a poor prognosis. Assessment of the mutation status of the FLT3 (fms related tyrosine kinase 3) recept...
End User License Agreement
CAREFULLY READ THE TERMS OF THIS END USER LICENSE AGREEMENT BETWEEN YOU AND INVIVOSCRIBE, INC., A CALIFORNIA CORPORATION (“LICENSOR”) BEFORE ACCESSING OR USING Invivoscribe Software (THE “PRODUCT”). BY ACCESSING OR USING THE PRODUCT, OR CLICKING BELOW TO ACKNOWLEDGE YOUR ACCEPTANCE OF THE TERMS AND CONDITIONS OF THIS AGREEMENT, YOU, AS THE USER OF THE PRODUCT, IN WHATEVER CAPACITY (EACH AN “AUTHORIZED USER”), AGREE TO THE TERMS OF THIS AGREEMENT. IF YOU DO NOT AGREE TO ALL OF THE TERMS OF THIS AGREEMENT, DO NOT ACCESS OR USE THE PRODUCT, OR CLICK BELOW TO ACKNOWLEDGE YOUR ACCEPTANCE OF THE TERMS AND CONDITIONS OF THIS AGREEMENT. BY USING THE PRODUCT, YOU ASSERT THAT YOU ARE AN AUTHORIZED REPRESENTATIVE OF THE END USER WITH AUTHORITY TO ENTER INTO THIS AGREEMENT.
This End User License Agreement (“Agreement”) is made and entered into by and between INVIVOSCRIBE, INC., a California corporation (“Licensor”) and You (either an individual or a legal entity), the “Licensee,” as defined herein for the licensing and usage of the Licensor’s software. Licensee acknowledges and agrees that Licensee’s right to use the software in any manner shall be controlled by this Agreement and that such use shall be strictly in accordance with the terms and conditions of this Agreement.
©2022 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its affiliates, or (as to the trademarks of others used herein) their respective owners.